GATT and Patent Extensions
Executive SummaryThe controversy over GATT patent extensions continues to be legally messy and the ultimate outcome is unclear, with contests looming or likely to loom over recent FDA and PTO rulings as well as the wording of certain stipulations in GATT.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.